This clinical trial is focused on studying the long-term effects of a treatment called spesolimab in people with a skin condition known as Generalized Pustular Psoriasis (GPP). GPP is a rare and severe form of psoriasis characterized by widespread pustules, which are small, pus-filled blisters on the skin. The treatment being tested, spesolimab, is a medication of biological origin, meaning it is made from living organisms or their products. It is administered either as a solution for infusion, which is delivered directly into the bloodstream through a vein, or as a solution for injection using a pre-filled syringe.

The purpose of this study is to evaluate the long-term safety and effectiveness of spesolimab in patients who have previously participated in spesolimab trials and are eligible to continue treatment. Participants in this study will receive spesolimab over an extended period, with the aim of understanding how well the treatment works and how safe it is for long-term use. The study will monitor for any side effects that may occur during the treatment period, which can last up to 252 weeks.

Throughout the study, researchers will also observe how the treatment affects the symptoms of GPP, such as the presence of pustules and overall skin condition. The study will help determine if spesolimab can maintain its effectiveness over time and improve the quality of life for those living with GPP. Participants will be closely monitored by healthcare professionals to ensure their safety and well-being during the trial.